Request Demo
Last update 31 May 2025
Botulinum toxin A(Anterios, Inc.)
Last update 31 May 2025
Overview
Basic Info
Drug Type Toxin |
Synonyms Botulinum toxin A topical, ANT 1207, ANT-1207 |
Target |
Action inhibitors |
Mechanism SNAP25 inhibitors(Synaptosomal-associated protein 25 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
9
Clinical Trials associated with Botulinum toxin A(Anterios, Inc.)IRCT20220121053776N1
Evaluation of the efficacy, safety, satisfaction and tolerability of treatment with diluted botulinum toxin A in comparison with intralesional triamcinolone in patients undergone PDL laser for Hypertrophic erythematous scars: A blinded randomized controlled clinical trial
ChiCTR1800019282
A randomized, open label, parallel controlled trial for botulinum toxin A injection combined with minoxidil in the treatment of androgenic alopecia
EUCTR2017-003117-25-AT
Longitudinal chemodenervation effects of botulinum toxin A after intramuscular application and the impact of physical activity - BoNT- physical activity and chemodenervation
100 Clinical Results associated with Botulinum toxin A(Anterios, Inc.)
Login to view more data
100 Translational Medicine associated with Botulinum toxin A(Anterios, Inc.)
Login to view more data
100 Patents (Medical) associated with Botulinum toxin A(Anterios, Inc.)
Login to view more data
100 Deals associated with Botulinum toxin A(Anterios, Inc.)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Botulinum toxin A(Anterios, Inc.) | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Primary Axilary Hyperhidrosis | Phase 2 | United States | 03 Jun 2015 | |
| Crow's feet | Phase 2 | United States | 01 May 2011 | |
| Lateral Canthal Lines | Phase 2 | United States | 01 May 2011 | |
| Acne Vulgaris | Phase 2 | United States | 01 Jan 2011 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 145 | Vehicle (Vehicle) | pfyarrmdyt = qnesrncnms cnmzdtkomv (hddeundpgg, rgeclamrtg - qihhkfghpp) View more | - | 20 Sep 2017 | ||
(ANT-1207 Dose 1) | pfyarrmdyt = qhhfffvhrr cnmzdtkomv (hddeundpgg, rskfquxqzc - wcchkdxbaz) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free